KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exact Sciences (EXAS) Revenue (2016 - 2025)

Exact Sciences (EXAS) has disclosed Revenue for 16 consecutive years, with $878.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Revenue rose 23.12% to $878.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 billion, a 17.69% increase, with the full-year FY2025 number at $3.2 billion, up 17.69% from a year prior.
  • Revenue was $878.4 million for Q4 2025 at Exact Sciences, up from $850.7 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $878.4 million in Q4 2025 to a low of $402.1 million in Q1 2021.
  • A 5-year average of $617.8 million and a median of $625.2 million in 2023 define the central range for Revenue.
  • Biggest YoY gain for Revenue was 61.72% in 2021; the steepest drop was 1.6% in 2021.
  • Exact Sciences' Revenue stood at $473.8 million in 2021, then increased by 16.71% to $553.0 million in 2022, then increased by 16.98% to $646.9 million in 2023, then increased by 10.29% to $713.4 million in 2024, then rose by 23.12% to $878.4 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Revenue are $878.4 million (Q4 2025), $850.7 million (Q3 2025), and $811.1 million (Q2 2025).